{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:39:49Z","timestamp":1794037189905,"version":"4.8.0"},"reference-count":53,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"European & Developing Countries Clinical Trials Partnership 3","award":["101195533"],"award-info":[{"award-number":["101195533"]}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"crossref","award":["101195533"],"award-info":[{"award-number":["101195533"]}],"id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,7,14]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"\n Introduction<\/jats:title>\n Mpox remains endemic in the Democratic Republic of the Congo (DRC), with pregnant women at increased risk of severe disease and adverse outcomes. The WHO has called for data on mpox vaccination in high-risk groups, but no clinical trial has assessed the safety or immunogenicity of mpox vaccines in this population. The modified vaccinia Ankara\u2013Bavarian Nordic (MVA-BN) vaccine, a third-generation, highly attenuated, non-replicating, live virus vaccine, has shown an excellent safety profile in adolescents and adults, including immunocompromised individuals, and is expected to be safe during pregnancy.<\/jats:p>\n <\/jats:sec>\n \n Methods and analysis<\/jats:title>\n \n Pregnancy & Infancy mPox Vaccine study is a phase 3, open-label trial that aims to evaluate the safety, reactogenicity and immunogenicity of the MVA-BN vaccine in pregnant and postpartum women in Boende, the DRC, compared with adults of the POX-MVA-045 study (\n NCT06549530<\/jats:ext-link>\n ) in DRC and Uganda. A total of 359 pregnant women (16\u201335 years old, in their second or third trimester of pregnancy) are being enrolled and randomised to receive the homologous MVA-BN vaccine regimen at a 28-day interval, with the first dose administered either before 32 weeks of gestation during pregnancy or within 72 hours postpartum (3:2 ratio randomisation). An additional, non-randomised group will receive post-exposure prophylaxis following confirmed mpox exposure. Primary immunogenicity analyses will assess the non-inferiority of neutralising antibody titres in pregnant women compared with those in non-pregnant adults. Primary safety analyses will compare reactogenicity in pregnant women to that observed in adults and safety in pregnant women to safety observed in adults and women vaccinated in the immediate postpartum period. Secondary analysis will evaluate neutralising antibody titres and total binding antibody concentrations over time for pregnant and postpartum women compared with adults and each other.\n <\/jats:p>\n <\/jats:sec>\n \n Ethics and dissemination<\/jats:title>\n The trial integrates ancillary care pathways, local capacity building and formative workshops that co-developed research tools. Ethical approvals were obtained from institutional and national review boards in the DRC and Belgium. Results will be shared with local communities, national stakeholders and global health agencies.<\/jats:p>\n <\/jats:sec>\n \n Trial registration number<\/jats:title>\n \n NCT06844500<\/jats:ext-link>\n & PACTR202511506487215.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-115710","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:20:26Z","timestamp":1785241226000},"page":"e115710","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["PregInPoxVac maternal protocol: a phase 3 trial evaluating maternal immunogenicity and safety of the MVA-BN vaccine in the Democratic Republic of the Congo"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct06549530","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06844500","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06549530","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06844500","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06549530","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06549530","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4358-5443","authenticated-orcid":false,"given":"Paulina","family":"Morales Ruiz","sequence":"first","affiliation":[{"name":"Global Health Institute (GHI), University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Milolo Tshilumba","sequence":"additional","affiliation":[{"name":"Global Health Institute (GHI), University of Antwerp, Antwerp, Belgium"},{"name":"Clinical Research and Immunization, Department of Tropical Medicine, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-441X","authenticated-orcid":false,"given":"Kirsten","family":"Maertens","sequence":"additional","affiliation":[{"name":"Centre for the Evaluation of Vaccination (CEV), University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivi","family":"Maketa","sequence":"additional","affiliation":[{"name":"Clinical Research and Immunization, Department of Tropical Medicine, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Primo","family":"Kimbulu","sequence":"additional","affiliation":[{"name":"Clinical Research and Immunization, Department of Tropical Medicine, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felly","family":"Mitashi","sequence":"additional","affiliation":[{"name":"Clinical Research and Immunization, Department of Tropical Medicine, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7515-4820","authenticated-orcid":false,"given":"Mahmoud","family":"Abu Azoum","sequence":"additional","affiliation":[{"name":"Global Health Institute (GHI), University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustave","family":"Kasereka","sequence":"additional","affiliation":[{"name":"Clinical Research and Immunization, Department of Tropical Medicine, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Bisumba","sequence":"additional","affiliation":[{"name":"Global Health Institute (GHI), University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Salloum","sequence":"additional","affiliation":[{"name":"Global Health Institute (GHI), University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2473-2814","authenticated-orcid":false,"given":"Freddy","family":"Bikoli-Bolombo","sequence":"additional","affiliation":[{"name":"Global Health Institute (GHI), University of Antwerp, Antwerp, Belgium"},{"name":"Clinical Research and Immunization, Department of Tropical Medicine, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe","family":"Le Prevost","sequence":"additional","affiliation":[{"name":"UCL Innovative Clinical Trials Unit, University College London, London, UK"},{"name":"Fondazione Penta ETS, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwen","family":"Lemey","sequence":"additional","affiliation":[{"name":"Global Health Institute (GHI), University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geofrey","family":"Makenga","sequence":"additional","affiliation":[{"name":"Global Health Institute (GHI), University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8642-1249","authenticated-orcid":false,"given":"Pierre","family":"Van Damme","sequence":"additional","affiliation":[{"name":"Centre for the Evaluation of Vaccination (CEV), University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Van Geertruyden","sequence":"additional","affiliation":[{"name":"Global Health Institute (GHI), University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hypolite","family":"Muhindo-Mavoko","sequence":"additional","affiliation":[{"name":"Clinical Research and Immunization, Department of Tropical Medicine, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mitashi","sequence":"additional","affiliation":[{"name":"Clinical Research and Immunization, Department of Tropical Medicine, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tr\u00e9sor","family":"Zola Matuvanga","sequence":"additional","affiliation":[{"name":"Clinical Research and Immunization, Department of Tropical Medicine, University of Kinshasa, Kinshasa, Congo (the Democratic Republic of the)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5422-0194","authenticated-orcid":false,"given":"Ynke","family":"Larivi\u00e8re","sequence":"additional","affiliation":[{"name":"Global Health Institute (GHI), University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"2026072805201453000_16.7.e115710.1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010141","article-title":"The changing epidemiology of human monkeypox-A potential threat? A systematic review","volume":"16","author":"Bunge","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2026072805201453000_16.7.e115710.2","doi-asserted-by":"crossref","DOI":"10.3390\/v15081649","article-title":"Mpox (Monkeypox) in Pregnancy: Viral Clade Differences and Their Associations with Varying Obstetrical and Fetal Outcomes","volume":"15","author":"Schwartz","year":"2023","journal-title":"Viruses"},{"key":"2026072805201453000_16.7.e115710.3","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70102","article-title":"Monkeypox Outbreak in the Democratic Republic of Congo: A Comprehensive Review of Clinical Outcomes, Public Health Implications, and Security Measures","volume":"12","author":"Salomon","year":"2024","journal-title":"Immun Inflamm Dis"},{"key":"2026072805201453000_16.7.e115710.4","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix260"},{"key":"2026072805201453000_16.7.e115710.5","doi-asserted-by":"crossref","DOI":"10.3390\/v16071123","article-title":"High Rates of Miscarriage and Stillbirth among Pregnant Women with Clade I Mpox (Monkeypox) Are Confirmed during 2023-2024 DR Congo Outbreak in South Kivu Province","volume":"16","author":"Schwartz","year":"2024","journal-title":"Viruses"},{"key":"2026072805201453000_16.7.e115710.6","doi-asserted-by":"crossref","unstructured":"Hasivirwe Vakaniaki E , Barhishindi I , Mubiala A , et al . Maternal and neonatal outcomes after clade i mpox virus infection in pregnancy: a pooled prospective observational study in the democratic republic of the congo. SSRN [Preprint] 2025. doi:10.2139\/ssrn.5577836","DOI":"10.2139\/ssrn.5577836"},{"key":"2026072805201453000_16.7.e115710.7","doi-asserted-by":"crossref","first-page":"103622","DOI":"10.1016\/j.ijoa.2022.103622","article-title":"The impact of monkeypox in pregnant patients on obstetric anesthesiology","volume":"53","author":"Williams","year":"2023","journal-title":"Int J Obstet Anesth"},{"key":"2026072805201453000_16.7.e115710.8","doi-asserted-by":"crossref","first-page":"102758","DOI":"10.1016\/j.jiph.2025.102758","article-title":"Mpox in pregnancy: Unraveling the maternal-fetal risks of a re-emerging disease, a narrative review","volume":"18","author":"Rossi","year":"2025","journal-title":"J Infect Public Health"},{"key":"2026072805201453000_16.7.e115710.9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ajog.2022.08.017","article-title":"Monkeypox in pregnancy: virology, clinical presentation, and obstetric management","volume":"227","author":"Dashraath","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"2026072805201453000_16.7.e115710.10","first-page":"245","article-title":"Case report: clinical presentation of Monkeypox in pregnancy","volume":"224","author":"Garc\u00eda-Hern\u00e1ndez","year":"2024","journal-title":"Rev Clin Esp (Barc)"},{"key":"2026072805201453000_16.7.e115710.11","unstructured":"World Health Organization . A coordinated research roadmap Mpox virus: Immediate research next steps to contribute to control the outbreak.2024:2\u20139."},{"key":"2026072805201453000_16.7.e115710.12","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-79-5-1159"},{"key":"2026072805201453000_16.7.e115710.13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells","volume":"79 (Pt 2)","author":"Drexler","year":"1998","journal-title":"J Gen Virol"},{"key":"2026072805201453000_16.7.e115710.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.05.095"},{"key":"2026072805201453000_16.7.e115710.15","doi-asserted-by":"crossref","first-page":"4758","DOI":"10.1016\/j.vaccine.2014.06.034","article-title":"Ischemic cardiac events and other adverse events following ACAM2000\u00ae smallpox vaccine in the Vaccine Adverse Event Reporting System","volume":"32","author":"McNeil","year":"2014","journal-title":"Vaccine"},{"key":"2026072805201453000_16.7.e115710.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.05.004"},{"key":"2026072805201453000_16.7.e115710.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195897","article-title":"Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial","volume":"13","author":"Overton","year":"2018","journal-title":"PLoS ONE"},{"key":"2026072805201453000_16.7.e115710.18","unstructured":"European Medicines Agency . Summary of product characteristics\u2013imvanex. 2022."},{"key":"2026072805201453000_16.7.e115710.19","doi-asserted-by":"crossref","first-page":"e1230","DOI":"10.1016\/S2214-109X(22)00284-4","article-title":"Monkeypox vaccines in pregnancy: lessons must be learned from COVID-19","volume":"10","author":"Khalil","year":"2022","journal-title":"Lancet Glob Health"},{"key":"2026072805201453000_16.7.e115710.20","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/vaccines12080825","article-title":"Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the Congo","volume":"12","author":"Kavunga-Membo","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2026072805201453000_16.7.e115710.21","doi-asserted-by":"crossref","unstructured":"Weidenthaler H , Vidojkovic S , Martin BK , et al . Real-world safety data for MVA-BN: Increased frequency of syncope following intradermal administration for immunization against mpox disease. Vaccine 2024;42. doi:10.1016\/j.vaccine.2024.05.072","DOI":"10.1016\/j.vaccine.2024.05.072"},{"key":"2026072805201453000_16.7.e115710.22","unstructured":"Clinicaltrial.gov . A phase 2 randomized multisite trial to inform public health strategies involving the use of MVA-BN Vaccine for Mpox. 2025."},{"key":"2026072805201453000_16.7.e115710.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00128-6"},{"key":"2026072805201453000_16.7.e115710.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial","volume":"19","author":"Anywaine","year":"2022","journal-title":"PLoS Med"},{"key":"2026072805201453000_16.7.e115710.25","doi-asserted-by":"crossref","first-page":"e1743","DOI":"10.1016\/S2214-109X(23)00410-2","article-title":"Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone","volume":"11","author":"Choi","year":"2023","journal-title":"Lancet Glob Health"},{"key":"2026072805201453000_16.7.e115710.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200072"},{"key":"2026072805201453000_16.7.e115710.27","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/infdis\/jiac283","article-title":"Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign","volume":"227","author":"Nyombayire","year":"2023","journal-title":"J Infect Dis"},{"key":"2026072805201453000_16.7.e115710.28","doi-asserted-by":"crossref","unstructured":"Pischel L , Martini BA , Yu N , et al . Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. Vaccine 2024;42. doi:10.1016\/j.vaccine.2024.06.021","DOI":"10.1016\/j.vaccine.2024.06.021"},{"key":"2026072805201453000_16.7.e115710.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0327590","article-title":"Awareness campaigns and strengthened prevention as alternatives to banning: Preventing zoonotic diseases from wildlife in the Democratic Republic of Congo","volume":"20","author":"Yambayamba","year":"2025","journal-title":"PLoS ONE"},{"key":"2026072805201453000_16.7.e115710.30","unstructured":"CAID . Cellulle d\u2019Analyses des indicateurs de d\u00e9veloppement. Boende, 2015."},{"key":"2026072805201453000_16.7.e115710.31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.4269\/ajtmh.23-0581","article-title":"Healthcare Providers\u2019 and Frontline Workers\u2019 Experiences of an Ebola Vaccine Trial in the Boende Health District of the Democratic Republic of the Congo","volume":"111","author":"Zola Matuvanga","year":"2024","journal-title":"Am J Trop Med Hyg"},{"key":"2026072805201453000_16.7.e115710.32","unstructured":"Cellule d\u2019Analyse des indicateurs de d\u00e9veloppement. Tshuapa, 2024."},{"key":"2026072805201453000_16.7.e115710.33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-046835","article-title":"Open-label, randomised, clinical trial to evaluate the immunogenicity and safety of a prophylactic vaccination of healthcare providers by administration of a heterologous vaccine regimen against Ebola in the Democratic Republic of the Congo: the study protocol","volume":"11","author":"Larivi\u00e8re","year":"2021","journal-title":"BMJ Open"},{"key":"2026072805201453000_16.7.e115710.34","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1016\/j.vaccine.2022.04.094","article-title":"Setting-up an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned","volume":"40","author":"Zola Matuvanga","year":"2022","journal-title":"Vaccine"},{"key":"2026072805201453000_16.7.e115710.35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/17470161231194139","article-title":"Researchers\u2019 responsibilities in resource-constrained settings: experiences of implementing an ancillary care policy in a vaccine trial in the Democratic Republic of the Congo","volume":"20","author":"Lemey","year":"2024","journal-title":"Res Ethics"},{"key":"2026072805201453000_16.7.e115710.36","unstructured":"Clinicaltrials.gov . Open-label, multicenter immunogenicity and safety study of MVA-BN vaccine in children from 2 years to less than 12 years of age compared to adults for the prevention of smallpox, mpox, and related orthopoxvirus infections. 2025."},{"key":"2026072805201453000_16.7.e115710.37","unstructured":"Bavarian Nordic A\/S . POX-MVA-045 open-label, multicenter immunogenicity and safety trial of MVA-BN\u00ae vaccine in children from 2 years to less than 12 years of age compared to adults for the prevention of smallpox, mpox, and related orthopoxvirus infection. 2024."},{"key":"2026072805201453000_16.7.e115710.38","unstructured":"World Health Organization . Joint statement on strengthening clinical trials 2025. 2025."},{"key":"2026072805201453000_16.7.e115710.39","unstructured":"Clinicaltrials.gov . Phase 3 maternal safety & immunogenicity trial of MVA-BN\u00ae in DRC (PregInPoxVac). 2025."},{"key":"2026072805201453000_16.7.e115710.40","doi-asserted-by":"crossref","first-page":"7587","DOI":"10.1016\/j.vaccine.2023.11.030","article-title":"Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: Challenges, mitigations, and lessons learned","volume":"41","author":"Larivi\u00e8re","year":"2023","journal-title":"Vaccine"},{"key":"2026072805201453000_16.7.e115710.41","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.vaccine.2015.01.072","article-title":"Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials","volume":"33","author":"Donken","year":"2015","journal-title":"Vaccine"},{"key":"2026072805201453000_16.7.e115710.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.10.056"},{"key":"2026072805201453000_16.7.e115710.43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1494"},{"key":"2026072805201453000_16.7.e115710.44","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2021-005726","article-title":"Algorithm for the support of non-related (serious) adverse events in an Ebola vaccine trial in the Democratic Republic of the Congo","volume":"6","author":"Lemey","year":"2021","journal-title":"BMJ Glob Health"},{"key":"2026072805201453000_16.7.e115710.45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0050090","article-title":"The Ancillary-Care Obligations of Medical Researchers Working in Developing Countries","volume":"5","year":"2008","journal-title":"PLoS Med"},{"key":"2026072805201453000_16.7.e115710.46","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2024-015259","article-title":"An ancillary care policy in a vaccine trial conducted in a resource-constrained setting: evaluation and policy recommendations","volume":"9","author":"Lemey","year":"2024","journal-title":"BMJ Glob Health"},{"key":"2026072805201453000_16.7.e115710.47","unstructured":"PregInPoxVac Consortium . Pregnancy & infancy Mpox vaccine study. PregInPoxVac; 2025."},{"key":"2026072805201453000_16.7.e115710.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02669-2"},{"key":"2026072805201453000_16.7.e115710.49","unstructured":"World Health Organization . Mpox - democratic republic of the Congo. 2024."},{"key":"2026072805201453000_16.7.e115710.50","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-025-00813-x","article-title":"Increased testing is needed for Mpox in DR Congo to urgently curb disease spread","volume":"5","author":"Imani-Musimwa","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"2026072805201453000_16.7.e115710.51","doi-asserted-by":"crossref","first-page":"7076","DOI":"10.1016\/j.vaccine.2023.10.057","article-title":"The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials\u2019 records between 2018 and 2023","volume":"41","author":"Salloum","year":"2023","journal-title":"Vaccine"},{"key":"2026072805201453000_16.7.e115710.52","unstructured":"Okapi R . L\u2019Assembl\u00e9e nationale se mobilise contre le paludisme en RDC. 2024."},{"key":"2026072805201453000_16.7.e115710.53","unstructured":"Brighton Collaboration SPEAC Project . Cohort event monitoring (CEM) protocol template for active safety surveillance after vaccination with mpox vaccines (1.0). 2024."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-115710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:20:35Z","timestamp":1785241235000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-115710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7,28]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/bmjopen-2025-115710"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-115710","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}